ARCTIC: Durvalumab With or Without Tremelimumab as Third-Line or Later Treatment for Metastatic Non-Small Cell Lung Cancer

Annals of Oncology - United Kingdom
doi 10.1016/j.annonc.2020.02.006
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer

Journal of Cancer
Oncology
2020English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

Third- Or Later-Line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice

Clinical Colorectal Cancer
OncologyGastroenterology
2019English

Irinotecan Monotherapy as Third-Line or Later Treatment in Advanced Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2017English

Radiotherapy With or Without Concomitant Chemotherapy as Pre- Or Postoperative Therapy in Non-Small Cell Lung Cancer

Journal of Cancer Science & Therapy
2012English

Durvalumab for Non-Resectable Stage IIIB Non-Small Cell Lung Cancer—a Small Step or a Big Leap?

Translational Lung Cancer Research
Oncology
2018English

Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-Ii Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-Small Cell Lung Cancer

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy